---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件（201931712353812.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文氯化钾注射液处方资料（仅供参考）

【英文名称】Potassium Chloride in 0.45% Sodium Chloride Injection

【注意】

氯化钠注射液中的氯化钾，USP禁用于以下患者：

已知对氯化钾和/或氯化钠过敏（见警告）。

临床上显着的高钾血症（见警告）

【适用证】

氯化钠注射液中的氯化钾，USP被认为是水和电解质的来源。

【用法用量】

重要管理说明：

氯化钠注射液中的氯化钾，USP用于使用无菌设备进行静脉输注。

为避免危及生命的高钾血症，请不要在氯化钠注射液中使用氯化钾，USP作为静脉推注（即，使用注射器连接到静脉通路时手动静脉注射），无需定量输液装置（参见警告）。

请勿将柔性塑料容器串联连接，以避免因主容器中可能残留的空气而导致空气栓塞。

在通气静脉内给药装置上将通气孔设置到关闭位置，以防止空气栓塞。

使用没有任何连接的专用线路以避免空气栓塞。

不要对柔性塑料容器中的静脉注射液加压以增加流速，以避免由于容器中残余空气的不完全排空而引起的空气栓塞。

中心或外周静脉输注途径的选择应取决于最终输注液的渗透压。渗透压大于或等于约900mOsm / L的溶液必须通过中心导管输注。

在输注之前，目视检查溶液中的颗粒物质和变色。解决方案应该清楚，不应有沉淀物。除非溶液清洁且容器未损坏，否则不要进行管理。

在可能的情况下，在所有肠胃外溶液的给药期间，建议使用最终过滤器。

剂量信息：

特定氯化钾和氯化钠制剂的选择，剂量，体积，速率和给药持续时间取决于患者的年龄，体重和临床及代谢状况以及伴随治疗，给药应由有静脉输液治疗经验的医师。

可根据患者的临床需要指示额外的电解质补充。可以将添加剂引入容器中;但是，某些添加剂可能不相容。评估塑料容器的所有添加剂，以获得所得制剂的相容性和稳定性。如果可能，请咨询药剂师。

如果根据医生的明智判断，建议引入添加剂，请使用无菌技术。添加后，如果有变色和/或沉淀物，不溶性配合物或晶体的外观，请勿使用。添加添加剂时要彻底混合。不要存放含有添加剂的溶液。丢弃任何未使用的部分。

快速纠正低钠血症和高钠血症具有潜在危险（严重神经系统并发症的风险）。为了避免在给药期间出现渗透性脱髓鞘综合征（ODS）等并发症，请遵循重要的给药说明，监测血清钠和氯浓度，液体状态，酸碱平衡和神经系统并发症的体征。

【INDICATIONS AND USAGE】

Potassium Chloride in Sodium Chloride Injection, USP is indicated as a source of water and electrolytes.

【CONTRAINDICATIONS】

Potassium Chloride in Sodium Chloride Injection, USP is contraindicated in patients with:

Known hypersensitivity to potassium chloride and/or sodium chloride (see WARNINGS).

Clinically significant hyperkalemia (see WARNINGS)

【DOSAGE AND ADMINISTRATION】

Important Administration Instructions：

Potassium Chloride in Sodium Chloride Injection, USP is intended for intravenous infusion using sterile equipment.

To avoid life threatening hyperkalemia, do not administer Potassium Chloride in Sodium Chloride Injection, USP as an intravenous push (i.e., intravenous injection manually with a syringe connected to the intravenous access) without a quantitative infusion device (see WARNINGS).

Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container.

Set the vent to the closed position on a vented intravenous administration set to prevent air embolism.

Use a dedicated line without any connections to avoid air embolism.

Do not pressurize intravenous solutions contained in flexible plastic containers to increase flow rates in order to avoid air embolism due to incomplete evacuation of residual air in the container.

The choice of a central or peripheral venous route of infusion should depend on the osmolarity of the final infusate. Solutions with osmolarity of greater than or equal to approximately 900 mOsm/L must be infused through a central catheter.

Prior to infusion, visually inspect the solution for particulate matter and discoloration. The solution should be clear and there should be no precipitates. Do not administer unless solution is clear and container is undamaged.

Use of final filter is recommended during administration of all parenteral solutions, where possible.

Dosing Information：

The choice of the specific potassium chloride and sodium chloride formulation, dosage, volume, rate and duration of administration is dependent upon the age, weight and clinical and metabolic condition of the patient and concomitant therapy, and administration should be determined by a physician experienced in intravenous fluid therapy.

Additional electrolyte supplementation may be indicated according to the clinical needs of the patient. Additives can be introduced to the container; however, some additives may be incompatible. Evaluate all additions to the plastic container for compatibility and stability of the resulting preparation. Consult with a pharmacist, if available.

If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. After addition, if there is a discoloration and/or the appearance of precipitates, insoluble complexes or crystals, do not use. Mix thoroughly when additives have been introduced. Do not store solutions containing additives. Discard any unused portion.

Rapid correction of hyponatremia and hypernatremia is potentially dangerous (risk of serious neurologic complications). To avoid complications such as osmotic demyelination syndrome (ODS) during administration, follow the important administration instructions, monitor serum sodium and chloride concentrations, fluid status, acid-base balance, and signs of neurologic complications.

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件（201931712353812.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------